Wire · operational-macro
Mirum Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business Update
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 4 November 2026 · Fusion42 review
Mirum Pharmaceuticals reported strong Q3 2026 financial results with $185.7M in net product sales and raised full-year sales guidance. The company received FDA approval for ATEBRIOZ for FOP, announced multiple positive late-stage trial readouts, and plans several regulatory submissions and approvals in 2027, including orphan drug designation for brelovitug in HDV.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
You face a market opening as Mirum advances multiple rare disease drugs toward approval, signalling easier FDA paths and growing rare disease commercialisation. If your biotech targets rare liver or genetic diseases, now is the time to engage payers or prepare for partnerships ahead of 2027 regulatory milestones.
◆ Coverage
1 source · 4 Nov 2026
◆ Related on Wire
◆ Topics